Market Place
Sourcing Support
All News #Library
Biotech
Actuate Therapeutics Reveals Doubling Survival Rate
14 Apr 2026 //
GLOBENEWSWIRE
Actuate Therapeutics Set For $200M+ Pediatric Priority Review
24 Mar 2026 //
PHARMIWEB
Actuate Studies Elraglusib With RAS Inhibitors
09 Mar 2026 //
GLOBENEWSWIRE
Actuate Therapeutics to Present at 36th Oppenheimer Sciences Conf
24 Feb 2026 //
GLOBENEWSWIRE
Actuate Expands Pipeline with Elraglusib Ph 1/2 Program in Cancer
21 Jan 2026 //
GLOBENEWSWIRE
Actuate Therapeutics Shows Extended Survival Benefit
12 Jan 2026 //
GLOBENEWSWIRE
ASCO GI 2026 Selects Actuate`s Phase 2 Data for Presentation
18 Dec 2025 //
GLOBENEWSWIRE
Actuate Therapeutics Publishes Positive Phase II Data
15 Dec 2025 //
GLOBENEWSWIRE
Actuate`s Pancreatic Cancer Drug Boosts Survival by 3 Months
03 Jun 2025 //
FIERCE BIOTECH
Cancer-focused Actuate is latest biotech on Nasdaq after $22.4M IPO
15 Aug 2024 //
FIERCE BIOTECH
Clinical-stage cancer biotech Actuate latest to eye summer IPO
28 May 2024 //
FIERCE BIOTECH
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.